11.02
+3.96%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Genfit
Its shares trade on Euronext Paris under the ticker GNFT.PA. It has been listed since 19 December 2006. In the fiscal year to 31 December 2025, it reported revenue of €65.4m and a net loss of €86.0m. At that date it held total assets of €157.9m and shareholders' equity of −€23.6m.
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France. The company went IPO on 2006-12-19. The firm is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The firm targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 19 Dec 2006
- Employees
- 175
- Website
- genfit.fr ↗
Leadership
Pay as last reported
- Mr. Jean-Francois MouneyChairman of the Board of Directors, since 1999€382,684
- Mr. Pascal PrigentChief Executive Officer€681,945
- Mr. Eric BacletIndependent Vice-Chairman of the Board of Directors€68,416
- Mr. Thomas BaetzChief Financial Officer
- Mr. Pascal CaiseyChief Operating Officer
- Ms. Stefanie MagnerExecutive Vice President - International Legal Affairs, Chief Compliance Officer
- Ms. Emilie DesodtExecutive Vice President of Human Resources
- Mr. John BrozekExecutive Vice President - Data and Information Technology
- Mr. Tom HuijbersExecutive Vice President - Regulatory
- Ms. Sakina Sayah-JeanneExecutive Vice President - Research & Translational Science
- Dr. Dean HumChief Scientific Officer, since 2022€140,597
- Dr. Carol AddyChief Medical Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 74
- Environment
- 82
- Social
- 99
- Governance
- 39
- Women in the workforce
- 62.89308%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Genfit SA has several strengths that contribute to its competitive advantage in the market. These strengths include:
Weaknesses
- Despite its strengths, Genfit SA also faces certain weaknesses that can hinder its growth and performance. These weaknesses include:
Opportunities
- Genfit SA can leverage various opportunities in the market to drive its future success. These opportunities include:
Threats
- Genfit SA must also be aware of potential threats that can affect its business and market position. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.